Sangamo Therapeutics
Unknown based on the provided page content, US · Founded 1995 · 229 employees on LinkedIn · 4 known investors
Find your way into Sangamo Therapeutics
416 people in our graph share verified history with the Sangamo Therapeutics team — schools, employers, funds. One of them is your warm intro.
Sam Blackmanunlockedknows Sandy Macrae · together at GlaxoSmithKline (overlapped)
×4knows the team · via GlaxoSmithKline
×4knows the team · via University of Cambridge
×2knows the team · via University of Glasgow
knows the team · via Sangamo Therapeutics
Sangamo Therapeutics develops gene-editing therapeutics using zinc finger and modular integrase platforms to treat genetic diseases including hemophilia, Fabry disease, and neuropathy. The company is currently undergoing Chapter 11 reorganization and conducting clinical trials for various therapeutic applications.
Founders & leadership
SM
Sandy MacraeinChief Executive OfficerSandy Macrae is President and CEO of Sangamo Therapeutics, a company developing gene-editing and genomic medicine therapeutics for genetic diseases including hemophilia and Fabry disease.
Investors · 4
In the news
Frequently asked questions
- What does Sangamo Therapeutics do?
- Sangamo Therapeutics develops gene-editing therapeutics using zinc finger and modular integrase platforms to treat genetic diseases including hemophilia, Fabry disease, and neuropathy. The company is currently undergoing Chapter 11 reorganization and conducting clinical trials for various therapeutic applications.
- Who are Sangamo Therapeutics's investors?
- Sangamo Therapeutics's investors include California Technology Ventures, Foothill Ventures, Foresite Capital, Ridgeback Capital.
- Where is Sangamo Therapeutics headquartered?
- Sangamo Therapeutics is headquartered in Unknown based on the provided page content, US.